TY - JOUR
T1 - Risk factors and clinical characteristics of the depressive state induced by pegylated interferon therapy in patients with hepatitis C virus infection
T2 - A prospective study
AU - Kawase, Kohei
AU - Kondo, Kenji
AU - Saito, Takeo
AU - Shimasaki, Ayu
AU - Takahashi, Atsushi
AU - Kamatani, Yoichiro
AU - Kawabe, Naoto
AU - Hashimoto, Senju
AU - Ikeda, Masashi
AU - Kubo, Michiaki
AU - Yoshioka, Kentaro
AU - Iwata, Nakao
N1 - Funding Information:
This study was supported by grants from ?Integrated Research on Neuropsychiatric Disorders? carried out under the Strategic Research Program for Brain Sciences (SRPBS) by the Ministry of Education, Culture, Sports, and Technology (MEXT) of Japan and the Japan Agency for Medical Research and Development (AMED). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Aim: Pegylated interferon (PegIFN) therapies for hepatitis C virus (HCV) infection often induce a depressive state. This study aimed to identify the risk factors for and clinical characteristics of PegIFN-induced depressive state. Methods: Sixty-nine subjects with HCV who received PegIFN therapy were enrolled. Before beginning therapy, all subjects were evaluated using the Neuroticism–Extraversion–Openness Five-Factor Inventory and the List of Threatening Events Questionnaire. Beck Depression Inventory (BDI) scores were also evaluated at baseline, 2–4 weeks after initiating therapy, and every 4 weeks thereafter. Results: During the study, 18 subjects (24.3%) developed a depressive state (BDI ≥ 10). A bimodal peak of onset was observed during the early (2–8 weeks) and late (after 20 weeks) therapy phases. Moreover, we observed that baseline BDI scores (odds ratio [OR] = 1.40, P = 0.0104) and neuroticism (OR = 1.14, P = 0.0275) were significant risk factors for developing a depressive state. To determine the specific characteristics of this condition, we compared the BDI subscales between the ‘PegIFN-induced’ and ‘general’ depressive state reported previously. We found that the score at ‘somatic symptoms’ was higher in the ‘PegIFN-induced’ group. Conclusion: Our results indicate the following: (i) PegIFN-induced depressive state most frequently develops during the first 8 weeks of therapy; (ii) baseline BDI and neuroticism scores are risk factors for PegIFN-induced depressive state; and (iii) the core symptoms of PegIFN-induced depressive state are different from those of ‘general’ depression.
AB - Aim: Pegylated interferon (PegIFN) therapies for hepatitis C virus (HCV) infection often induce a depressive state. This study aimed to identify the risk factors for and clinical characteristics of PegIFN-induced depressive state. Methods: Sixty-nine subjects with HCV who received PegIFN therapy were enrolled. Before beginning therapy, all subjects were evaluated using the Neuroticism–Extraversion–Openness Five-Factor Inventory and the List of Threatening Events Questionnaire. Beck Depression Inventory (BDI) scores were also evaluated at baseline, 2–4 weeks after initiating therapy, and every 4 weeks thereafter. Results: During the study, 18 subjects (24.3%) developed a depressive state (BDI ≥ 10). A bimodal peak of onset was observed during the early (2–8 weeks) and late (after 20 weeks) therapy phases. Moreover, we observed that baseline BDI scores (odds ratio [OR] = 1.40, P = 0.0104) and neuroticism (OR = 1.14, P = 0.0275) were significant risk factors for developing a depressive state. To determine the specific characteristics of this condition, we compared the BDI subscales between the ‘PegIFN-induced’ and ‘general’ depressive state reported previously. We found that the score at ‘somatic symptoms’ was higher in the ‘PegIFN-induced’ group. Conclusion: Our results indicate the following: (i) PegIFN-induced depressive state most frequently develops during the first 8 weeks of therapy; (ii) baseline BDI and neuroticism scores are risk factors for PegIFN-induced depressive state; and (iii) the core symptoms of PegIFN-induced depressive state are different from those of ‘general’ depression.
UR - http://www.scopus.com/inward/record.url?scp=84987654226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84987654226&partnerID=8YFLogxK
U2 - 10.1111/pcn.12424
DO - 10.1111/pcn.12424
M3 - Article
C2 - 27471075
AN - SCOPUS:84987654226
VL - 70
SP - 489
EP - 497
JO - Psychiatry and Clinical Neurosciences
JF - Psychiatry and Clinical Neurosciences
SN - 1323-1316
IS - 11
ER -